<DOC>
	<DOCNO>NCT00818844</DOCNO>
	<brief_summary>The purpose study compare macular volume patient treat 3-month course topical Nepafenac ( 0.1 % solution ) patient treat placebo course follow epiretinal membrane surgery .</brief_summary>
	<brief_title>Role Nepafenac Reducing Macular Volume After Epiretinal Membrane Surgery</brief_title>
	<detailed_description />
	<mesh_term>Epiretinal Membrane</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<criteria>18 year age old , race either sex . Able understand sign inform consent approve Institutional Review Board . Must agree comply study visit schedule study requirement . Must vision loss associate idiopathic epiretinal membrane secondary retinal edema . Must preoperative central foveal thickness great 300 micron . Prior cataract surgery must least 6 month postoperative . Other protocoldefined inclusion criterion may apply . Vision loss associate maculopathies idiopathic epiretinal membrane secondary retinal edema ( e.g . branch retinal vein occlusion , central retinal vein occlusion , wet macular degeneration , diabetic retinopathy , posterior uveitis ) . Dry macular degeneration ( drusen ) central geographic atrophy . Concomitant cataract surgery perform time study vitrectomy . Prior vitrectomy surgery study eye ( ) . Prior macula laser treatment study eye ( ) . Prior periocular steroid injection study eye ( ) within precede 6 month . Prior cataract surgery study eye ( ) within last 6 month . Any systemic ocular disease disorder , complicate factor structural abnormality would negatively affect conduct outcome study . Use topical ocular medication study period . Antibiotics ( systemic topical ) outside study protocol may use within 7 day preoperative/baseline visit anytime visit duration study . Women childbearing potential use reliable mean birth control . Women pregnant lactating . Enrollment one person per household time . Enrollment investigator staff , family member investigator , family member investigator 's staff , individual live household individual . Participation investigational drug device study within 30 day enter study . Note : Patients may eye enrol study provide 2nd eye enrollment take place 30 day completion first eye . Second eye receive study treatment first eye . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Nepafenac</keyword>
	<keyword>vitrectomy surgery</keyword>
	<keyword>Epiretinal membrane surgery</keyword>
</DOC>